Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combo Products Meeting Will Address Cross-Labeling, Dual Applications

This article was originally published in The Gray Sheet

Executive Summary

Diagnostic ultrasound, magnetic resonance imaging and contrast agent companies will hold a series of meetings with FDA to address issues related to their respective device and drug premarket approvals

You may also be interested in...



CDRH Review Of Expanded Imaging Agent Indications Urged By NEMA

CDRH should serve as the lead reviewer for premarket applications of already-approved contrast agents indicated for use with diagnostic imaging devices, according to Philips Medical Systems VP-Quality & Regulatory Affairs Terry Sweeney

CDRH Review Of Expanded Imaging Agent Indications Urged By NEMA

CDRH should serve as the lead reviewer for premarket applications of already-approved contrast agents indicated for use with diagnostic imaging devices, according to Philips Medical Systems VP-Quality & Regulatory Affairs Terry Sweeney

Combo Products Collaborative, Consultative Review Document Outlines SOPs

FDA's interpretation of "primary mode of action," the principle underlying jurisdictional assignment of combination products, will be open for stakeholder comment during a second public meeting on the topic

Related Content

UsernamePublicRestriction

Register

LL010986

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel